State Scrutiny Of Drug Pricing Intensifies With Rise Of PDABs
Source: Life Science Leader
By Meena Datta, Kim Schroer, and Trevor Wear
More than five years after state price transparency laws began spreading throughout the country, states have opened up a new front in their battle against what they deem to be excessively high prescription drug prices through the establishment of prescription drug affordability boards (PDABs).
access the Magazine Article!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.
Subscribe to Life Science Leader
X
Subscribe to Life Science Leader
This website uses cookies to ensure you get the best experience on our website. Learn more